Nasofan (Fluticasone Propionate)

Fluticasone propionate binds to glucocorticoid receptors inside nasal mucosal cells. This binding alters gene transcription, suppressing the release of inflammatory cytokines, chemokines and adhesion molecules. The result is decreased inflammatory cell infiltration, reduced edema and less mucus, providing symptom relief.

The prescribed dose of Nasofan is determined by the treating clinician based on the patient’s age, severity of symptoms and specific indication. Typical regimens involve one or two sprays per nostril once or twice daily, but the exact schedule must follow the prescriber’s instructions.

Safety data for fluticasone propionate nasal spray in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant. Healthcare providers should discuss individual circumstances and consider alternative therapies when appropriate.

To request Nasofan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Nasofan’s active ingredient, fluticasone propionate, is a high‑potency glucocorticoid with low systemic bioavailability, similar to other nasal steroids like mometasone or budesonide. Compared with lower‑potency agents, fluticasone often provides stronger anti‑inflammatory effects at comparable doses, but individual response and tolerability may vary.

Nasofan should be stored at room temperature, below 25 °C, in its original packaging. Keep the container tightly closed, protect it from moisture and direct sunlight, and avoid freezing. Do not refrigerate unless specifically instructed on the label.

Nasofan is administered as a nasal spray. The user should gently blow the nose, tilt the head slightly forward, insert the nozzle into one nostril, and press the actuator while breathing in gently through the nose. The same procedure is repeated for the other nostril if required.

Serious risks, though rare, include adrenal suppression with prolonged high‑dose use, perforation of the nasal septum, opportunistic fungal infections of the nasal cavity, and severe allergic reactions such as anaphylaxis. Patients should report unusual symptoms like persistent fatigue, severe nosebleeds or visual changes to their healthcare provider promptly.

Nasofan should be avoided in individuals with known hypersensitivity to fluticasone propionate or any excipients in the formulation. It is also contraindicated in patients with active untreated nasal infections, recent nasal surgery, or those who have experienced severe adverse reactions to other intranasal corticosteroids.